| Assay ID | Title | Year | Journal | Article |
|---|
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1833083 | Inhibition of H-PGDS (unknown origin) using fluorescent probe by competition binding assay | 2021 | Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
| Discovery of a Highly Potent and Selective Degrader Targeting Hematopoietic Prostaglandin D Synthase via In Silico Design. |
| AID1685234 | Binding affinity to recombinant human HPGDS expressed in Escherichia coli BL21 (DE3) measured after 1 hr by fluorescence polarization assay | 2021 | ACS medicinal chemistry letters, Feb-11, Volume: 12, Issue:2
| Development of a Hematopoietic Prostaglandin D Synthase-Degradation Inducer. |
| AID1685231 | Induction of CRBN-mediated HPGDS degradation in human KU812 cells at 10 to 100 nM incubated for 24 hrs followed by compound washout and further incubated for 6 hrs in compound-free medium by Western blot analysis | 2021 | ACS medicinal chemistry letters, Feb-11, Volume: 12, Issue:2
| Development of a Hematopoietic Prostaglandin D Synthase-Degradation Inducer. |
| AID1858479 | PROTAC activity at CRBN/H-PGDS in human KU812 cells assessed as reduction in H-PGDS levels incubated for 24 hrs by Western blotting analysis | 2022 | RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
| Structure-activity relationship study of PROTACs against hematopoietic prostaglandin D |
| AID1685230 | Inhibition of HPGDS in human KU812 cells assessed as reduction in PGD2 level at 10 to 100 nM incubated for 24 hrs followed by A23187 treatment and measured after 30 mins by ELISA | 2021 | ACS medicinal chemistry letters, Feb-11, Volume: 12, Issue:2
| Development of a Hematopoietic Prostaglandin D Synthase-Degradation Inducer. |
| AID1685227 | Inhibition of HPGDS in human KU812 cells assessed as reduction in PGD2 level at 10 to 100 nM incubated for 24 hrs followed by A23187 treatment and measured after 30 mins and subsequent compound washout then further incubated for 6 hrs in compound-free med | 2021 | ACS medicinal chemistry letters, Feb-11, Volume: 12, Issue:2
| Development of a Hematopoietic Prostaglandin D Synthase-Degradation Inducer. |
| AID1858489 | Inhibition of H-PGDS in human KU812 cells assessed as reduction in A23187-stimulated PGD2 levels at 10 nM preincubated for 24 hrs followed by A23187 stimulation for 30 mins by ELISA analysis | 2022 | RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
| Structure-activity relationship study of PROTACs against hematopoietic prostaglandin D |
| AID1685239 | Induction of HPGDS degradation in human KU812 cells at 1 uM measured after 6 hrs in presence of pomalidomide by Western blot analysis | 2021 | ACS medicinal chemistry letters, Feb-11, Volume: 12, Issue:2
| Development of a Hematopoietic Prostaglandin D Synthase-Degradation Inducer. |
| AID1685233 | Inhibition of recombinant human HPGDS expressed in Escherichia coli BL21 (DE3) measured after 3 mins by spectrophotometric analysis | 2021 | ACS medicinal chemistry letters, Feb-11, Volume: 12, Issue:2
| Development of a Hematopoietic Prostaglandin D Synthase-Degradation Inducer. |
| AID1833090 | Suppression of PGD2 production in human KU812 cells measured in presence of compound 43 up to 3000 pM incubated for 6 hrs by LC-MS analysis | 2021 | Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
| Discovery of a Highly Potent and Selective Degrader Targeting Hematopoietic Prostaglandin D Synthase via In Silico Design. |
| AID1399746 | Binding affinity to full length recombinant human N-terminal His6-tagged H-PGDS expressed in Escherichia coli BL21(DE3) by SPR analysis | 2018 | Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16
| Characterization of crystal water molecules in a high-affinity inhibitor and hematopoietic prostaglandin D synthase complex by interaction energy studies. |
| AID1858478 | Binding affinity to recombinant human H-PGDS incubated for 1 hrs by competitive fluorescence polarization assay | 2022 | RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
| Structure-activity relationship study of PROTACs against hematopoietic prostaglandin D |
| AID1685249 | Inhibition of recombinant human HPGDS using [14C]-PGH2 as substrate preincubated for 1 min in presence of MgCl2 followed by substrate addition and measured after 45 mins by radioactive imaging analysis | 2021 | ACS medicinal chemistry letters, Feb-11, Volume: 12, Issue:2
| Development of a Hematopoietic Prostaglandin D Synthase-Degradation Inducer. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |